Obesity – Pipeline Review, H2 2016
- Pages: 537
- Published: November 2016
- Report Code: GMDHC8621IDB
Global Markets Direct’s, ‘Obesity – Pipeline Review, H2 2016’, provides an overview of the Obesity pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Obesity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Obesity
The report reviews pipeline therapeutics for Obesity by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Obesity therapeutics and enlists all their major and minor projects
The report assesses Obesity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Obesity
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Obesity
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Obesity pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Abeome Corporation
Acylin Therapeutics Inc
Advinus Therapeutics Ltd
Aegis Therapeutics, LLC
Akron Molecules AG
Alize Pharma SAS
Amabiotics SAS
Amgen Inc.
Aoxing Pharmaceutical Company, Inc
Arena Pharmaceuticals, Inc.
AstraZeneca Plc
Asubio Pharma Co., Ltd.
Athersys, Inc.
Biophytis SAS
BioRestorative Therapies, Inc.
Boehringer Ingelheim GmbH
Braasch Biotech LLC
C3 Jian, Inc
Carmot Therapeutics Inc
Chronos Therapeutics Limited
CohBar, Inc.
CoMentis, Inc.
Connexios Life Sciences Pvt. Ltd.
Corium International, Inc.
Daiichi Sankyo Company, Limited
Diabetica Limited
DiscoveryBiomed, Inc.
Eli Lilly and Company
Esperion Therapeutics, Inc.
Eternygen GmbH
Evotec AG
F. Hoffmann-La Roche Ltd.
FibroGen Inc
Galenea Corp.
Gila Therapeutics Inc
Gilead Sciences, Inc.
GlaxoSmithKline Plc
GTx, Inc.
HanAll Biopharma Co., Ltd.
Handok Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Hyundai Pharmaceutical Co., Ltd.
Immungenetics AG
Intarcia Therapeutics, Inc.
Ionis Pharmaceuticals, Inc.
Ixchel Pharma, LLC
Jenrin Discovery, Inc.
Johnson & Johnson
Kowa Company, Ltd.
Lead Discovery Center GmbH
Leading BioSciences, Inc.
LEO Pharma A/S
LG Life Science LTD.
Lotus Pharmaceutical Co., Ltd.
M Pharmaceutical Inc.
Magnus Life Ltd
MAKScientific, LLC
MedImmune LLC
Merck & Co., Inc.
Mitochon Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
NeuroNano Pharma Inc
NGM Biopharmaceuticals, Inc.
NIBEC
Nordic Bioscience A/S
Novo Nordisk A/S
ObeTherapy Biotechnology
Ogeda SA
Omeros Corporation
OPKO Biologics Ltd
OPKO Health, Inc.
Orbis Biosciences Inc
Orexigen Therapeutics, Inc.
Pfizer Inc.
PharmaIN Corporation
Poxel SA
Progenra, Inc.
Prometheon Pharma, LLC
ReCyte Therapeutics, Inc.
Renova Therapeutics Inc
Reviva Pharmaceuticals Inc.
Saniona AB
Sanofi
Selvita S.A.
Seoul Pharma Co., Ltd.
Shionogi & Co., Ltd.
Sinil Pharmaceutical Co., Ltd
Sorrento Therapeutics Inc
Sumitomo Dainippon Pharma Co., Ltd.
Takeda Pharmaceutical Company Limited
Toray Industries, Inc.
Umecrine AB
Vicore Pharma AB
Viking Therapeutics, Inc.
WhanIn Pharmaceutical Co., Ltd.
Xenetic Biosciences (UK) Limited
XL-protein GmbH
Yuyu Pharma, Inc.
Zafgen Inc.
Zealand Pharma A/S
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.